Equidyne has received US FDA 510(k) clearance to market its large capacity 0.5ml needle-free drug delivery system, the INJEX50. The new system, together with Equidyne's FDA-cleared 0.3ml INJEX30, allows the company to compete for over 80% of the subcutaneous injection market. The INJEX50 also opens the door to new clinical markets which require doses greater than 0.3ml, such as local anaesthesia, vaccinations and human growth hormone, says the San Diego, California company.
FDA clears Equidyne's large capacity INJEX system:
Equidyne has received US FDA 510(k) clearance to market its large capacity 0.5ml needle-free drug delivery system, the INJEX50. The new system, together with Equidyne's FDA-cleared 0.3ml INJEX30, allows the company to compete for over 80% of the subcutaneous injection market. The INJEX50 also opens the door to new clinical markets which require doses greater than 0.3ml, such as local anaesthesia, vaccinations and human growth hormone, says the San Diego, California company.